Filing Details
- Accession Number:
- 0001387131-22-003861
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-22 18:37:33
- Reporting Period:
- 2022-03-18
- Accepted Time:
- 2022-03-22 18:37:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
887247 | Adamis Pharmaceuticals Corp | ADMP | Pharmaceutical Preparations (2834) | 820429727 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1038322 | Phd J Dennis Carlo | C/O Adamis Pharmaceuticals Corporation 11682 El Camino Real, Ste 300 San Diego CA 92130 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-03-18 | 10,490 | $0.60 | 285,867 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 150,709 | Indirect | By Dennis and Allison Carlo Joint Living Trust |
Common Stock | 5,883 | Indirect | By A. Carlo as custodian for child. |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The shares were sold to pay the withholding and tax obligations relating to the issuance of shares following the vesting of RSUs previously granted to the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5954 to $0.6143, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.